The headline reads as positive (71% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The rest of the picture is mixed, so the headline alone is not enough for a clear call.
Stocks › SNDX
Syndax Pharmaceuticals Inc (SNDX) stock analysis
SKIP 3% confidence · analysed Oct 15, 2026
On Oct 15, 2026, our model rated Syndax Pharmaceuticals Inc (SNDX) SKIP with 3% confidence at a price of $13.65. That means the signals cancel out; the model sees no clear edge either way.
Analysed price$13.65
Technical picture
The 14-day RSI is 19, below 30, which is oversold territory: sellers have pushed hard recently. Oversold stocks often bounce, but they can stay weak for a while.
MACD is below its signal line, so short-term momentum is pointing down.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is about normal (1.1x the 20-day average).
Trend structure and money flow
Market structure shows a bearish break of structure (BOS): price broke a recent swing low in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $25.24 and the swing low is $16.66; traders often treat these as resistance and support.
Fundamentals
The company reports a profit margin of -87.5% and revenue growth of +91.8%.
In its latest quarter it earned $-0.55 per share, which missed the $-0.44 analysts expected, with revenue +91.8% year over year.
Wall Street's average rating is 1.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $37.27.
The next earnings report is expected around Nov 2, 2026; prices often move sharply around earnings.
Research notes
SNDX’s bull case rests on growing commercial traction from Revuforj and Niktimvo, plus potential upside from Revuforj label expansion and multiple frontline AML trials expected to generate data in late 2026. The bear case is that the company just lost an important pipeline opportunity after axatilimab’s MAXPIRe Phase 2 idiopathic pulmonary fibrosis trial missed its primary endpoint, prompting Syndax to discontinue development in that indication. The major recent catalyst was the IPF failure, which drove the stock down roughly 16% and intensified concerns about pipeline concentration, cash burn, competition, and Revuforj’s boxed-warning risk. Despite the setback, analysts remain broadly bullish, with reported consensus targets substantially above the stock’s mid-teens trading level.
The model's one-paragraph read
No clear edge (SKIP) — composite score -0.03 (SKIP). Technicals: RSI 18.88, MACD bearish, price below SMA50. Fundamentals: margin -87.5%, revenue growth 91.8%. Financial results: YoY revenue +91.8%, last EPS surprise -25.0%, next earnings 2026-11-02. Smart Money Concepts: BOS bearish (trend continuation). FinGPT news read: positive. Internet research: SNDX’s **bull case** rests on growing commercial traction from Revuforj and Niktimvo, plus potential upside from Revuforj label expansion and multiple frontline AML trials expected to generate data in late 2026. The **bear case** is that the company just lost an important pipeline opportunity after axatilimab’s MAXPIRe Phase 2 idiopathic pulmonary fibrosis trial missed its primary endpoint, prompting Syndax to discontinue development in that indication. The major recent catalyst was the IPF failure, which drove the stock down roughly 16% and intensified concerns about pipeline concentration, cash burn, competition, and Revuforj’s boxed-warning risk. Despite the setback, analysts remain broadly bullish, with reported consensus targets substantially above the stock’s mid-teens trading level. Reference price $13.65; no trade levels (SKIP).
Past ratings for SNDX
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 15, 2026 | SKIP | 3% | $13.65 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on SNDX
Oct 15, 2026 · Syndax's Revuforj (revumenib) Named to TIME's Best Inventions of 2026 List
- Oct 15, 2026: Syndax's Revuforj (revumenib) Named to TIME's Best Inventions of 2026 List (GlobeNewswire)
Frequently asked questions
Is SNDX a buy right now?
As of Oct 15, 2026, our automated model rates Syndax Pharmaceuticals Inc (SNDX) SKIP with 3% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does Syndax Pharmaceuticals Inc report earnings next?
The next earnings report is expected around Nov 2, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.